Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aura Biosciences, Inc. AURA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.75
+220.9%

Aura Biosciences, Inc. (AURA) is a Biotechnology company in the Healthcare sector, currently trading at $7.09. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is AURA = $23 (+220.9% upside).

Valuation: AURA trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.88.

Net income is $106M (loss), growing at -23.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $17M against $137M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 8.15 (strong liquidity). Debt-to-assets is 10.3%. Total assets: $169M.

Analyst outlook: 8 / 8 analysts rate AURA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$22.75
▲ 220.87% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Aura Biosciences, Inc., the average price target is $22.75, with a high forecast of $25.00, and a low forecast of $19.00.
Highest Price Target
$25.00
Average Price Target
$22.75
Lowest Price Target
$19.00

AURA SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 74/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AURA

✓
VALUE Pass
74/100
AURA trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25). Forward PEG 1.88 — overvalued. Analyst consensus target is $23, implying +224.4% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AURA: +0%/yr revenue is, -23.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet AURA: Debt-to-Equity (D/E) ratio 0.13 (conservative), Current ratio is 8.15 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
AURA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 8 / 8 analysts rate AURA as buy (100%). Analyst consensus target is $23 (+224.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.345-7.48
Volume287.74K
Avg Volume (30D)250.4K
Market Cap$454.83M
Beta (1Y)0.35
Share Statistics
EPS (TTM)-1.76
Shares Outstanding$60.34M
IPO Date2021-10-29
Employees106
CEOElisabet de los Pinos
Financial Highlights & Ratios
EBITDA$-111.66M
Net Income$-106.19M
Operating Income$-112.79M
Total Cash$144.24M
Total Debt$17.38M
Net Debt$-42.14M
Total Assets$169.43M
Price / Earnings (P/E)-4
Analyst Forecast
1Y Price Target$23.50
Target High$25.00
Target Low$19.00
Upside+231.5%
Rating ConsensusBuy
Analysts Covering8
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS05153U1079

Price Chart

Track all markets on TradingView
AURA
Aura Biosciences, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
4.35 52WK RANGE 7.48

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 IMTX
IMTX
Immatics N.V.
$10.95
+0.74%
 ORIC
ORIC
ORIC Pharmaceuticals, Inc.
$10.53
+1.25%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message